Eli Lilly's ($LLY) closely watched autoimmune treatment ixekizumab met its main goals in a Phase III psoriatic arthritis trial, rolling toward an FDA application and a shot at competing in a fast-crowding space. The drug would come up against Novartis' ($NVS) Cosentyx, which won approval in January, and a slate of forthcoming contenders. More from FierceBiotech